ARHGAP24 inhibits cell cycle progression, induces apoptosis and suppresses invasion in renal cell carcinoma

Gaosi Xu; Xiongbing Lu; Tianlun Huang; Jie Fan

doi:10.18632/oncotarget.10386

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Expression of Concern

This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.

ARHGAP24 inhibits cell cycle progression, induces apoptosis and suppresses invasion in renal cell carcinoma

Gaosi Xu _, Xiongbing Lu, Tianlun Huang and Jie Fan

PDF | HTML | How to cite

Oncotarget. 2016; 7:51829-51839. https://doi.org/10.18632/oncotarget.10386

Metrics: PDF 1484 views | HTML 3414 views | ?

Abstract

Gaosi Xu1,*, Xiongbing Lu2,*, Tianlun Huang1, Jie Fan1

1Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, China

2Department of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, China

*These authors have contributed equally to this work

Correspondence to:

Gaosi Xu, email: [email protected]

Keywords: renal cancer, ARHGAP24, proliferation, cell cycle, apoptosis

Received: March 14, 2016 Accepted: June 13, 2016 Published: July 2, 2016

ABSTRACT

Renal cell carcinoma (RCC) is the major cause of kidney malignancy-related deaths. Rho GTPases are key regulators in cancer cell metastasis. ARHGAP24, a Rac-specific member of the Rho GTPase-activating protein family, acts as a functional target of cancer cell migration and invasion. In the present study, we identified ARHGAP24 expression is downregulated in renal cancer tissues and is highly correlated with long-term survival in RCC patients. Therefore, we investigated the biological functions of ARHGAP24 in renal cancer cells. Ectopic expression of ARHGAP24 resulted in inhibited cell proliferation and arrested cell cycle in two renal cancer cell lines (786-0 and Caki-2); the results were confirmed by ARHGAP24 knocking down. In addition, ARHGAP24 significantly reduced the cell invasion ability and induced apoptosis in renal cancer cells. In addition, overexpressing ARHGAP24 impaired tumor formation in vivo. In summary, our results illustrated that ARHGAP24 plays a unique role in RCC progression as a tumor repressor.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10386

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

ARHGAP24 inhibits cell cycle progression, induces apoptosis and suppresses invasion in renal cell carcinoma

Abstract